Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis by Lories, Rik JU et al.
Available online http://arthritis-research.com/content/11/2/221
Page 1 of 8
(page number not for citation purposes)
Abstract
Targeted therapies that neutralize tumour necrosis factor are often
able to control the signs and symptoms of spondyloarthritis. How-
ever, recent animal model data and clinical observations indicate
that control of inflammation may not be sufficient to impede
disease progression toward ankylosis in these patients. Bone
morphogenetic proteins and WNTs (wingless-type like) are likely to
play an important role in ankylosis and could be therapeutic
targets. The relationship between inflammation and new bone
formation is still unclear. This review summarizes progress made in
our understanding of ankylosis and offers an alternative view of the
relationship between inflammation and ankylosis.
Introduction
The spondyloarthritides (SpAs) are a group of chronic
inflammatory diseases of the skeleton and associated soft
tissues. Different diagnostic entities that share clinical,
pathological and genetic characteristics are integrated into
this disease concept. These include ankylosing spondylitis
(AS), psoriatic arthritis (PsA), inflammatory bowel disease-
associated arthritis, reactive arthritis, juvenile SpA and
undifferentiated SpA [1]. The prevalence and burden of
SpAs, in particular AS and PsA, are at least as high as those
of rheumatoid arthritis (RA) [1-3]. Sacroiliitis and spinal
inflammation as well as peripheral arthritis and enthesitis,
often with a nonsymmetrical distribution, are typical clinical
features of these diseases. Extraskeletal manifestations
include psoriasis, inflammatory bowel disease and acute
anterior uveitis [1].
Clinical signs such as inflammatory pain, stiffness, swelling
and loss of function are caused by enthesitis, bone edema,
synovitis and joint effusion. The enthesis, an anatomical zone
in which fibers of the tendons, ligaments and capsules insert
into the bone through a fibrocartilaginous connection, is
hypothesized to be the primary disease localization in SpA
[4]. Entheses are found as a part of the joint organ or at extra-
articular sites [5,6]. The synovium and the underlying bone
marrow are in close contact and communication with the
entheses [5-7]. Although compelling evidence is lacking,
synovitis and osteitis in SpA can be understood by this close
anatomical relationship. Chemotaxis and accumulation of
inflammatory cells in combination with increased
angiogenesis are more likely to occur in the easily accessible
synovium and bone marrow than in the entheseal
fibrocartilage, which is relatively resistant to cell invasion and
neovascularization [6,7].
Although features of joint destruction can be dramatic, in
particular in some forms of PsA, skeletal damage in SpA is
only partially due to the loss of articular cartilage and bone
erosion. In contrast, new cartilage and bone formation,
presenting as ankylosing enthesopathy and leading to bony
spurs, syndesmophytes, enthesophytes and eventually joint
or spine ankylosis, are hallmark signs of these diseases. This
process of ankylosis contributes significantly to the perma-
nent disability of the patients, in particular in those suffering
from AS [8].
The introduction of targeted therapies, in particular anti-
tumour necrosis factor (TNF) drugs, has met unprecedented
success in the treatment of signs and symptoms of SpA
[9,10]. However, current radiographic follow-up data suggest
that these drugs do not affect the process of ankylosis [11-
13]. This apparent lack of structural effect is in sharp contrast
to what is seen for the erosive destruction of joints in RA [14]
and in PsA [15]. On the other hand, continuous treatment
with celecoxib, a cyclo-oxygenase II specific nonsteroidal anti-
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inflammatory drug, as compared with on-demand treatment,
does appear to influence ankylosis in AS [16].
These observations emphasize that insights into the
molecular mechanisms of ankylosis and into the relationship
between inflammation and new tissue formation in SpA are
essential. Ankylosis is a fairly slow process and may not be
seen in all patients [11-13,16]. In addition, the human tissue
samples that are needed to study these processes are
difficult to obtain, in particular in patients with axial disease.
Current understanding and further progress into the nature
and mechanisms of pathological new bone formation in SpA
are therefore largely based on data obtained in different
animal models, in imaging and biomarker studies.
Types of new bone formation
Two different types of physiological bone formation that take
place during embryonic development and growth are
recognized. Most skeletal elements are formed by a process
of endochondral bone formation. Mesenchymal cells conden-
sate into a so-called ‘anlagen’ and subsequently undergo
chondrogenic differentiation. Cells within this cartilaginous
mould of the skeletal element then differentiate into hyper-
trophic chondrocytes, their matrix is invaded by vessels and
the cartilage tissue is progressively replaced by bone matrix
synthesized by osteoblasts. Some bones, such as the
calvaria, form through membranous bone formation as
mesenchymal cells directly differentiate into osteoblasts that
produce the bone matrix.
Endochondral bone and membranous bone formation remain
important during postnatal growth. The growth plate is a
strictly organized process of endochondral bone formation.
The cortical bone further thickens through direct bone for-
mation. Bone homeostasis is determined by lifelong cycles of
local bone resorption by osteoclasts and new bone synthesis
by osteoblasts.
New bone formation can be required under pathological
circumstances [17]. Tissue responses to damage can lead to
tissue regeneration or repair, with the former resulting in
complete restoration and maintenance of function and
homeostasis. Tissue repair results in a surrogate tissue,
which at least partially restores function but which may
expose the patient to risk for functional failure in the future.
Abnormal or exaggerated tissue responses may lead to
further loss of function instead of restoration. These concepts
apply in particular to skeletal pathology, not only in SpA but
also in fracture healing, osteoarthritis, RA, diffuse idiopathic
skeletal hyperostosis (DISH, or Forestier’s disease) and rare
genetic disorders such as fibrodysplasia ossificans progressiva.
Fracture healing occurs through callus formation, which is a
process of mainly endochondral and partially direct bone
formation. This leads to healing and later remodelling in such
a way that the bone more or less regains its original shape. In
SpA, osteoarthritis, different forms of juvenile arthritis and
DISH, new bone formation is mainly orthotopic (in continuity
with existing bone) and appears to originate from the
cartilage-bone edge (osteoarthritis), the growth plate (juvenile
arthritis), or the enthesis and periosteum (SpA and DISH).
Although most of the bone formation appears to be
endochondral, direct bone formation also contributes.
Molecular mechanisms of new bone
formation: data from animal models
Bone formation during development and growth relies on a
number of molecular signalling pathways and their complex
interactions [18]. Increasing evidence supports the concept
that similar pathways are important during cartilage and bone
pathology, particularly with regard to new bone formation.
These pathways include bone morphogenetic protein (BMP),
wingless-type like (WNT), hedgehog, fibroblast growth
factors, notch and parathyroid hormone-like peptide signalling.
The potential roles played by BMP and WNT signalling in the
process of ankylosis in SpA were recently studied in various
animal models. Our group has used the spontaneous arthritis
model in ageing male DBA/1 mice to study molecular
mechanisms of ankylosing enthesitis [19]. These immuno-
logically normal mice develop oligoarthritis, especially in the
toes of the hind limbs, from the age of 12 weeks onward after
grouped caging of males from different litters. The disease
process is not characterized by primary synovitis but rather by
entheseal cell proliferation, cartilage and bone differentiation,
leading to peripheral joint ankylosis through orthotopic
endochondral bone formation. The model also presents with
dactylitis and destructive onychoperiostitis, which are well
recognized features of human PsA. This model also has its
limitations. Entheseal new cartilage and bone formation are
only seen in peripheral joints and not in the spine. Inflam-
mation with infiltration of immune populations into the joint
tissues is only of short duration and does not appear to
become a chronic process. These features are in contrast to
what is commonly seen in SpA. Nevertheless, the model
allows one to study molecular mechanisms of new tissue
formation and may provide some information about the
relationship between inflammation and ankylosis.
BMPs were originally identified as protein factors that can
induce an ectopic cascade of endochondral bone formation
in vivo, and are members of the transforming growth factor-β
superfamily. We demonstrated that different BMPs are
expressed during the process of ankylosis in male DBA/1
mice [20]. BMP2 is typically found in proliferating cells and
entheseal cells that commit their differentiation fate to chon-
drogenesis. BMP7 is recognized in prehypertrophic chondro-
cytes, whereas BMP6 is associated with hypertrophic
chondrocytes.
In the spontaneous ankylosing enthesitis model, systemic
over-expression of noggin, a BMP antagonist with broadligand affinity, inhibited the incidence, and clinical and histo-
morphological severity of arthritis in a dose-dependent
manner in both preventive and therapeutic experiments [20].
Progenitor cells committing to chondrogenic differentiation
were recognized as BMP target cells. The histomorphological
and molecular analysis of the experiments strongly suggested
that BMPs play a role in these initial phases of the disease
process.
However, the process of entheseal endochondral bone
formation is highly regulated at different stages. Endogenous
noggin is expressed in prehypertrophic and hypertrophic
chondrocytes and appears to play a role in reducing some
BMP signals in the replacement of hypertrophic chondro-
cytes by bone. A reduction in these endogenous noggin
levels in noggin haplo-insufficient mice was associated with
slower progression of ankylosis without affecting the initial
stages of the disease [21]. These data are consistent with
the complex role played by the BMP signalling pathway and
its antagonists as regulators of endochondral bone formation,
with different effects at distinct stages [18].
Interestingly, in a recent study, presented as an abstract, the
investigators used a similar strategy to inhibit BMP signalling
in aggrecan-induced spondylitis [22]. As our group demon-
strated for peripheral arthritis, over-expression of noggin
resulted in reduced spinal ankylosis, a feature of this murine
disease model. Different BMPs were found at similar disease
stages, and the target cells in this model appeared to be
identical to those in our earlier work. We also described such
BMP target cells in human entheseal lesions of the Achilles’
tendon insertion [20].
Another study identified dickkopf (DKK)1, an antagonist of
the WNT signalling pathway, as a potential key regulator of
the balance between erosive joint destruction and new bone
formation in inflammatory arthritis. Diarra and coworkers [23]
demonstrated that inhibition of DKK1 with specific antibodies
changed the histomorphological appearance of arthritis in
human TNF transgenic mice and other models, such as
collagen-induced and glucose-6-phosphate isomerase-
induced arthritis. The anti-DKK treated mice exhibited osteo-
phyte formation, which was absent in control antibody treated
mice.  Dkk1 is a TNF target gene through p38 mitogen-
activated protein kinase. Inhibition of DKK1 results in higher
osteoprotegerin levels, which block the activation of osteo-
clasts and hence bone erosion. In addition, bone formation
appears to be directly enhanced by stimulating WNT signal-
ling both in vitro and in vivo [23].
Both observations, blocking BMPs to inhibit ankylosis and a
WNT antagonist to stimulate it, albeit in different models,
raise questions about the potential interactions or primary
roles of these specific pathways. As mentioned above, BMPs
were originally identified as proteins that can induce
endochondral bone formation. In our studies, we identified
BMP2 as an early mediator of chondrogenesis in ankylosing
enthesopathy. Similar observations were reported in other
models of chondrogenesis and osteogenesis. Tsuji and
coworkers [24] demonstrated that limb-specific BMP2
knockout mice develop a normal skeleton but fail to maintain
bone growth and homeostasis in the limb after birth. Limb-
specific osteoporosis and spontaneous fractures occur, and
the natural healing process is absent. In addition, these limb-
specific BMP2 knockout mice fail to heal fractures in a
fracture model [24]. The authors hypothesize that before birth
loss of BMP2 in the limb can be compensated for by other
BMPs, whereas this seems no longer the case postnatally.
These findings indicate that developmental and postnatal
processes may have many similarities but can be different at
the molecular level. BMPs also play a critical role in the
development of osteophytes in models of osteoarthritis [25].
The effects of WNT signalling on bone formation appear
more complex. WNTs are a family of glycoproteins with an
array of functions during development, growth, tissue
homeostasis and disease. Some of the WNT ligands, in
particular WNT3A and WNT10B, are associated with direct
membranous bone formation during development and
growth, most likely by activation of the so-called canonical
WNT signalling pathway in which the nuclear translocation of
β-catenin acts as a downstream mediator [26]. The roles of
WNTs in endochondral bone formation are more difficult to
understand. WNT3A and WNT7A have been shown to inhibit
chondrogenesis in endochondral bone formation in develop-
mental models [26]. Other ligands, WNT5A and WNT5B,
appear to play opposite roles in determining the pace of
chondrocyte differentiation [27].
The complex and contrasting effects of WNT proteins are
further highlighted by studies of intracellular mediator β-
catenin. Over-expression of a constitutively active form of this
molecule in developing skeletal elements, mimicking en-
hanced WNT signalling, inhibited the early stages of chon-
drogenesis, whereas over-expression in later stages stimu-
lated maturation of the chondrocytes and bone formation
[28]. These observations are in accordance with a study in
which the progression of BMP2-induced endochondral bone
formation was found to be dependent on β-catenin [29].
Taken together, current evidence therefore suggests that
WNTs are most important in the later stages of endochondral
bone formation. WNTs signals stimulate progenitor cells into
the bone lineage and may inhibit early cartilage differentiation.
This negative effect on chondrogenic differentiation may also
be important postnatally, because WNTs appear to have a
negative effect on articular cartilage homeostasis. For
instance, mice that are deficient in the secreted WNT
antagonist frizzled related protein (FRZB) develop more
severe cartilage damage in osteoarthritis models, which is
associated with enhanced WNT signalling and increased
expression of WNT target genes [30]. Specific activation of
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leads to an osteoarthritic phenotype [31]. Surprisingly, the
same group also reported that lack of β-catenin in vivo leads
to loss of articular cartilage [32].
Based upon these data, we hypothesize that BMP family
members are critical in the early phases of ankylosis in SpA
and that WNT signalling through β-catenin plays a crucial
supportive role in this process, in particular in the progression
of endochondral bone formation (Figure 1).
Molecular mechanisms of new bone
formation in spondyloarthritis: human data
Progress in SpA research has been hindered by the relative
lack of human materials to study. Biopsies of the spine or
bone from peripheral joints are difficult to obtain. Corrective
surgical interventions are only rarely performed because the
balance between benefits and risks is unpredictable.
Moreover, surgical and autopsy materials are usually obtained
from patients with long-standing or end-stage disease.
Historical studies have demonstrated that both endochondral
and direct bone formation contribute to ankylosis in SpA [33].
New bone formation in SpA occurs mainly in continuity with
the existing skeleton. The different stages of the disease
process are more difficult to appreciate fully. Activation of
entheseal progenitor cells appears to play an important role.
A number of histology samples suggest that direct ossifi-
cation takes place in the spine. More recently, surgical
samples of spine and hip have been extensively studied.
Although most attention has been given to the involvement of
inflammatory cells in AS, areas of endochondral and direct
bone formation were also recognized [34-36].
Molecular analysis of pathology materials from SpA patients
is not only limited by the amount of tissue available but also to
some extent by the extensive processing of the calcified
tissues that is required. Transforming growth factor-β has
been detected in some samples, including biopsies of the
sacroiliac joints [37]. The specific involvement of this pleio-
tropic cytokine, which can have chondrogenic and osteo-
genic effects but is also an important immune modulator,
remains to be demonstrated. Our group has demonstrated
the presence of BMPs and activation of the BMP signalling
pathway in peripheral entheseal lesions in SpA [20].
Imaging studies appear very useful for further studying the
progression of SpA. Current approaches, in particular nuclear
magnetic resonance imaging (MRI), have mainly focused on
the detection of inflammatory changes. Progression of
ankylosis is studied using conventional radiography. Radio-
nuclide scans do not provide the required spatial resolution
to permit bone formation to be studied dynamically in
humans. It remains an open question whether approaches in
animal models, including enzyme-activated probes, will find
their way into clinical and translational patient imaging.
Serum biomarkers provide another means with which to study
the process of ankylosis. In their original study, Diarra and
coworkers [23] found that serum levels of DKK1 are very low
to absent in patients with AS as compared with those who
have RA. However, studies in other cohorts have yielded
conflicting results [38,39]. Markers of bone metabolism
suggest an upregulation of alkaline phosphatase activity in
AS patients treated with anti-TNF [40-42]. It is not clear
whether this increase is caused by enhanced trabecular bone
formation to restore inflammation-induced general bone loss
or by the specific development of syndesmophytes.
A relationship between inflammation and
new tissue formation
The existence or the nature of an eventual relationship
between inflammation and ankylosis has become a central
focus of research during the past couple of years. Pro-
inflammatory cytokines such as TNF have a negative effect on
chondrogenesis in in vitro systems [43]. We have demon-
strated that etanercept, a soluble TNF receptor, does not
affect ankylosing enthesopathy in the spontaneous arthritis
model in DBA/1 mice [43]. As indicated above, 2-year follow-
up cohorts suggested that, despite control of signs and
symptoms of the disease with anti-TNF, ankylosis may
progress [11-13].
These observations clearly highlight the critical question
whether inflammation and new tissue formation in SpA are
linked or uncoupled processes. The typical presentation of
the disease - with signs and symptoms caused by inflam-
mation prominent in the early phases, and ankylosis and the
resulting disability in the later stages - may suggest a
chronological order of events, but this is not supported by
specific evidence. Because human tissues, in particular
specimens from the spine, are not easily available, imaging
methods may help us to understand the nature of the
relationship between inflammation and ankylosis.
MRI can dynamically visualize the extent of inflammation in
patients. Different cohorts have recently been studied and the
conclusions about the relationship with tissue remodelling are
certainly not unequivocal [44,45]. Sites with active inflamma-
tion appear to be more prone to later development of syndes-
mophytes, but on the other hand syndesmophytes are not
adequately predicted by inflammation, as determined by MRI.
Probable mediators of new bone formation such as BMP2
are induced in different cell types (including synovial
fibroblasts and cartilage cells) by pro-inflammatory cytokines
such as TNF and interleukin-1 [46,47]. However, the direct
effect of BMP2, which was identified in early stages of
ankylosis in mice [20,22], may be counteracted by lack of
supportive WNT signalling, because DKK1 production is also
stimulated by TNF [23]. Of interest, downstream mediators of
TNF and interleukin-1 signalling such as nuclear factor-κB
and mitogen-activated protein kinases can also be triggered
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enthesis.
Further support for an uncoupling of inflammation and new
tissue formation may come from the observation that inhibi-
tion of osteoclasts, preventing bone erosion, does not affect
ankylosis in a mouse model [48]. This suggests that bone
erosion caused by osteoclasts is not necessary to trigger the
process of entheseal new bone formation. This is further
supported by human ultrasound data, which suggest that
erosions and spurs occur in anatomically different sites [49].
In this sense, ankylosis is not by default a repair process
initiated by damage to bone. However, damage to the fibrous
or cartilaginous enthesis could be the primary event.
A broader view on new bone formation in
spondyloarthritis
The apparent lack of effect on structural disease progression
in AS has provided impetus to consider different hypotheses
that apply to the relationship between inflammation and new
bone formation. The traditional concept that ankylosis is a
form of (excessive) repair has been translated into a new
paradigm in which a distinction is made between the chronic
active state of inflammation assumed to be typical for RA and
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Figure 1
Roles of BMPs and WNTs in endochondral bone formation. (a) Physiological endochondral bone formation is stimulated by bone morphogenetic
proteins (BMPs). Wingless-type like (WNT) signaling plays a supportive role in relation to BMPs. However, some WNTs have a negative effect on
early chondrocyte differentiation. (b) In the presence of inflammation, tumour necrosis factor (TNF) may stimulate BMP signalling but also the
expression of DKK1, which acts a WNT antagonist. The balance between TNF, BMP and WNT signalling may determine the onset and progression
of ankylosis. DKK, dickkopf.a more relapsing/remitting type of inflammation in SpA [50].
During this local remission phase, attempts at tissue repair
could occur and result in ankylosis. This hypothesis has two
important implications: first, early treatment could be useful to
prevent structural damage; and second, anti-TNF treatment
may lead to accelerated ankylosis in the short term but would
in the long term be beneficial to avoid structural disease
progression.
We propose an alternative hypothesis (Figure 2) based on
the assumption that the primary event that triggers SpA is still
unknown. We refer to this event as ‘entheseal stress’.
Activation of entheseal cells could lead to a double
phenomenon: triggering of new tissue formation and
production of pro-inflammatory molecules. The former can
lead to restoration of tissue integrity or tissue remodelling.
The latter phenomenon can develop into a chronic inflam-
matory process in which cytokines such as TNF play a pivotal
role. A number of known factors may contribute to chronicity:
the structural properties of HLA-B27; activation of the
immune system by the presence of inflammatory bowel
disease or infection; and polymorphisms in cytokines and
cytokine processing molecules that lead to either more
severe inflammation or delayed clearance of inflammation.
However, under most circumstances, in particular in the
absence of genetic predisposition, entheseal stress may not
lead to chronic changes and homeostasis is likely to be
restored.
In this paradigm, the development of SpA is dependent on a
multi-step process that leads to chronic or recurrent
inflammation but also to the triggering of new tissue
formation, completely or partially independent of inflam-
mation. The role of biomechanical factors that lead to stress
responses or microdamage in the enthesis should therefore
be further explored in this concept. Also, genetic factors, not
yet identified and different from those that determine disease
susceptibility, may have an impact on ankylosis. These
genetic factors may be shared with other bone-forming
diseases such as DISH and fibrodysplasia ossificans
progressiva. Accordingly, additional strategies will be
required to control new tissue formation in order to treat AS
and other SpA patients adequately in the long term.
Conclusions
Despite the enormous progress that has been made to
control signs and symptoms of disease in SpA, it remains
unclear whether these strategies will also result in reduced
disability by prevention of spinal or joint ankylosis.
Observations in animal models point in another direction, and
we therefore propose an alternative view of the relationship
between inflammation and ankylosis in SpA. Current data
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Figure 2
A view on the relationship between inflammation and ankylosis in SpA. The primary event is considered ‘entheseal stress’. Biomechanical factors
and microdamage are likely to play roles in this. Entheseal stress leads to triggering of an acute inflammatory reaction and of progenitor cells. In
most instances, the acute events go unnoticed and homeostasis is restored. Under specific circumstances, the acute events can turn into a chronic
situation in which inflammation and/or ankylosis are prominent. Different pathways regulate chronic inflammation and new tissue formation, but
these pathways are likely to influence each other. Genetic factors are likely to steer chronic inflammation and new tissue formation. For the latter
aspects, clues may be found in other bone-forming diseases. ERAP1, endoplasmic reticulum aminopeptidase 1; IBD, inflammatory bowel disease;
IL23R, interleukin-23 receptor.suggest that targeting of pathways such as BMPs and WNTs
is more likely to lead to prevention of structural damage and
its consequences.
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